29 reports

Tissue inhibitor of metalloproteinase ## (TIMP-##) showed statistically significant reduction; mean change of TIMP-##, -##. ## IU, P=##. ##.

  • Digestive System Disorder
  • Hospital
  • Immunotherapy
  • Stroke
  • TaiwanJ Pharmaceuticals Co., Ltd.

In December 2002, Amgen initiated another Phase II double-blind, placebo controlled, randomized, parallel-group clinical trial with multiple dose treatment of anti-il ## human monoclonal antibody (AMG ##) in patients with active rheumatoid arthritis who have previously failed one or more d

  • Digestive System Disorder
  • Therapy
  • United States
  • Company
  • Product Initiative

Eisai and Abbott (now Abbvie, Inc. ) signed a supplemental agreement for the joint development of the new indication, psoriasis, of the anti-rheumatic agent adalimumab in Japan.

  • Digestive System Disorder
  • Monoclonal Antibody
  • Stroke
  • United States
  • Product Initiative

In this trial, over ## patients will be randomized to receive one of four treatments ## mg ITI-##, ## mg ITI-##, ## mg risperidone (active control) or placebo in a ##:##:##:## ratio.

  • Digestive System Disorder
  • Neurological Disorder
  • Neurology
  • Therapy
  • BrainStorm Cell Therapeutics Inc.
  • GASTRITIS - PIPELINE BY BCWORLD PHARM CO LTD, H1 2018

IBS is one of the most common gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Company Operations
  • RedHill Biopharma Ltd.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Digestive System Disorder
  • Stroke
  • Therapy
  • United States
  • Product Initiative
  • GASTRITIS - PIPELINE BY BCWORLD PHARM CO LTD, H2 2018
  • GASTRITIS - PIPELINE BY DAEWON PHARM CO LTD, H2 2018

It also provides gastrointestinal agents, antirheumatic, narcotics, vitamin B## supplements and vitamin C supplements, anti-spasmodic, and autonomic nervous systems, among others.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Company Operations
  • RedHill Biopharma Ltd.

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Autoimmune Disease
  • Digestive System Disorder
  • Stroke
  • United States
  • Product Initiative
  • SUBJECTS WITH CROHN'S DISEASE. THE TRIAL WAS REGISTERED WITH THE U.S. NATIONAL INSTITUTES OF HEALTH.

ABBVIE REGISTERED THE FOLLOWING PHASE III TRIALS WITH THE TITLES RANDOMIZED, DOUBLE-BLIND, SELECT- PSA ## STUDY COMPARING ABT-## TO PLACEBO AND TO ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE A HISTORY OF INADEQUATE RESPONSE TO AT LEAST ONE NON-BIOLOGIC DISEASE M

  • Digestive System Disorder
  • Monoclonal Antibody
  • Stroke
  • United States
  • Company

Patients were randomized to receive AM- ## ##. ## mg/ mL, ##. ## mg/ mL or placebo in a ##:##:## ratio.

  • Digestive System Disorder
  • Monoclonal Antibody
  • Stroke
  • United States
  • Product Initiative

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Autoimmune Disease
  • Digestive System Disorder
  • Stroke
  • United States
  • Product Initiative

One external remote patient monitoring device consists of one external module or transmitter.

  • Cardiovascular Disease
  • Clinical Trial
  • Stroke
  • United States
  • Pfizer Inc.

It also provides gastrointestinal agents, anti-rheumatic, narcotics, vitamin B## supplements and vitamin C supplements, anti-spasmodic, and autonomic nervous systems, among others.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Molecular Diagnostics
  • Pathology
  • Therapy

In December 2002, Amgen initiated another Phase II double-blind, placebo controlled, randomized, parallel-group clinical trial with multiple dose treatment of anti-il ## human monoclonal antibody (AMG ##) in patients with active rheumatoid arthritis who have previously failed one or more d

  • Digestive System Disorder
  • Pathology
  • Therapy
  • United States
  • Product Initiative

The study will be a multiple dose, double-blind, placebo-controlled trial in patients with active RA who have previously failed one or more disease modifying anti-rheumatic drugs (DMARDs).

  • Digestive System Disorder
  • Medical Biotechnology
  • Stroke
  • World
  • Product Initiative

About CIMZIA® in the EU/ EEA In the EU, CIMZIA in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease-modifying anti-rheumatic drugs (DMARDs) including MTX.

  • Clinical Trial
  • Digestive System Disorder
  • Drug Development
  • Pharmaceutical
  • World

SEVENTY-ONE PERCENT OF ALL U. S.

  • Digestive System Disorder
  • Stroke
  • United States
  • Product Initiative
  • GlaxoSmithKline plc

It also provides gastrointestinal agents, antirheumatic, narcotics, vitamin B## supplements and vitamin C supplements, anti-spasmodic, and autonomic nervous systems, among others.

  • Chronic Disease
  • Digestive System Disorder
  • Stroke
  • United States
  • Amarin Corporation plc

The company provides cardiovascular, psychoneurotic, anti-cancer, antihistamine, antirheumatic and benign prostatic hyperplasia drugs.

  • Cardiovascular Disease
  • Digestive System Disorder
  • Stroke
  • Therapy
  • Esperion Therapeutics, Inc.

THE STUDY WILL BE A MULTIPLE DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH ACTIVE RA WHO HAVE PREVIOUSLY FAILED ONE OR MORE DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS).

  • Digestive System Disorder
  • Medical Biotechnology
  • United States
  • World
  • Product Initiative

SAL-## acts as an inhibitor of very late antigen ## (VLA-## or integrin alpha ## beta ##).

  • Digestive System Disorder
  • Stroke
  • United States
  • Company Operations
  • Valeant Pharmaceuticals International, Inc.
  • STROKE - PIPELINE BY SAVARA INC, H1 2018
  • STROKE - PIPELINE BY SHIN POONG PHARMCO LTD, H1 2018

The company provides cardiovascular, psychoneurotic, anti-cancer, antihistamine, antirheumatic and benign prostatic hyperplasia drugs.

  • Chronic Disease
  • Digestive System Disorder
  • Stroke
  • Company
  • Product Initiative
  • Clinical Trial Profile Snapshots

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Pharmaceutical
  • Therapy
  • World

The study conducted in Japan consisted of randomized, double-blind, placebo-controlled Phase III clinical trials in patients with rheumatoid arthritis with disease-modifying anti-rheumatic drugs (DMARDs).

  • Cancer
  • Digestive System Disorder
  • Stroke
  • Therapy
  • Daiichi Sankyo Company
  • ACUTE ISCHEMIC STROKE - PIPELINE BY SIMCERE PHARMACEUTICAL GROUP, H1 2016

In August 2011, AB Science registered a Phase II/ III multicenter, randomized, double-blind, controlled, ##-parallel groups study to compare efficacy and safety of masitinib at ## and ## mg/ kg/ day to methotrexate, with a randomization ##:##:##, in treatment of pati

  • Digestive System Disorder
  • Stroke
  • United States
  • Company Operations
  • AB Science SA

In August 2011, AB Science registered a Phase II/ III multicenter, randomized, double-blind, controlled, ##-parallel groups study to compare efficacy and safety of masitinib at ## and ## mg/ kg/ day to methotrexate, with a randomization ##:##:##, in treatment of pati

  • Digestive System Disorder
  • Stroke
  • United States
  • Company Operations
  • Product Initiative
  • ACUTE ISCHEMIC STROKE - PIPELINE BY SIMCERE PHARMACEUTICAL GROUP, H2 2016

In August 2011, AB Science registered a Phase II/ III multicenter, randomized, double-blind, controlled, ##-parallel groups study to compare efficacy and safety of masitinib at ## and ## mg/ kg/ day to methotrexate, with a randomization ##:##:##, in treatment of pati

  • Digestive System Disorder
  • Stroke
  • Therapy
  • Product Initiative
  • AB Science SA

It is one of the most common life-threatening genetic diseases, affecting between ## in ## and ## in ## people (##. ## - ##. ## per cent).

  • Digestive System Disorder
  • Endocrine Disease
  • Stroke
  • United States
  • Product Initiative
  • CIRRHOSIS. THE TRIAL WAS REGISTERED WITH THE U.S. NATIONAL INSTITUTES OF HEALTH.

Eisai and Abbott (now Abbvie, Inc. ) signed a supplemental agreement for the joint development of the new indication, psoriasis, of the anti-rheumatic agent adalimumab in Japan.

  • Digestive System Disorder
  • Monoclonal Antibody
  • Stroke
  • United States
  • AbbVie Inc.